First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
The panel is headed by DCGI Dr VG Somani with representatives from various state drug regulators and health ministry
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The medicine is now approved for eight indications across five different types of cancer in China.
First launched in 2005, pharmaREADY is a fully integrated, regulatory compliant, web-based platform to create, view, and manage global regulatory submissions
The World Health Organisation (WHO), has felt the need to conduct this training to build local capacities in poor countries to bridge the gap and enhance local production
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
In his previous assignment Perfetti was associated with Fabbrica Italiana Sintetici (F.I.S) as Chief Commercial Officer
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Subscribe To Our Newsletter & Stay Updated
